Cannasat Therapeutics and IntelGenx Enter into a Collaborative Agreement to Develop Novel Cannabinoid-based Products Based on Proprietary Drug Delivery Technologies
Canada Newswire, November 14, 2021
TORONTO, Nov. 14 /CNW/ – Cannasat Therapeutics Inc. (CTH: TSXV) and IntelGenx Corp. today announced a long-term collaborative agreement to co-develop novel cannabinoid-based products through a combination of Cannasat’s and IntelGenx’s proprietary drug delivery technologies. The collaboration will focus on the development and production of new formulations of cannabinoid pharmaceutical products, starting with Cannasat’s lead product, CAT 310.
Cannasat will leverage IntelGenx’s significant experience in developing unique oral, sublingual, and transdermal formulations. IntelGenx’s expertise will help address the challenges of achieving rapid onset, improving therapeutic efficacy, and minimizing central nervous system side effects with cannabinoids in treating disease indications such as neuropathic pain, movement disorders, and chronic pain.
“We are excited to work with IntelGenx to develop new cannabinoid pharmaceuticals that could potentially address a wide range of therapeutic indications such as neuropathic pain, where there is currently a large unmet medical need for new therapies. IntelGenx’s technology platform complements our existing drug delivery technologies and provides us an opportunity to broaden our growing intellectual property portfolio and product development pipeline. We are committed to expanding our arsenal of drug delivery technologies that can enhance the effectiveness of cannabinoid-based drugs,” said David Hill, CEO of Cannasat Therapeutics.
About IntelGenx Corp.
IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx has developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The company’s research and development pipeline includes products for the treatment of osteoarthritis, pain management, smoking cessation, and seasonal affective disorder.
About Cannasat Therapeutics
Cannasat Therapeutics is researching the therapeutic benefits of cannabis and developing new cannabinoid pharmaceutical products. Cannasat is pursuing two complementary business strategies. The first consists of development of novel cannabinoid-based pharmaceutical products through application of drug delivery technologies to be introduced to the market through the traditional regulatory drug approval process. The second is to promote medicinal cannabis research and education with Cannasat's business partner, Prairie Plant Systems Inc., the only government licensed grower and distributor of medicinal cannabis in Canada.
-30-
Contact Information
Cannasat Therapeutics Inc.
Andrew Williams
Vice President, Operations
W: (416) 703-2449 (Ext. 253)
F: (416) 703-8752
[email protected]
www.cannasat.com
IntelGenx Corp
Horst Zerbe
President and CEO
W: 514-331-7440 (ext. 201)
F: 514-331-0436
[email protected]
www.intelgenx.com
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.
